Bupropion is not a controlled substance under United States federal law. The Drug Enforcement Administration (DEA) has never placed it on any schedule of the Controlled Substances Act, meaning doctors can prescribe it without the special monitoring, prescription limits, or refill restrictions that apply to drugs like Adderall or Xanax. That said, bupropion has a more complicated relationship with misuse than most antidepressants, and its chemical structure sits surprisingly close to compounds that are tightly controlled.
Why the Question Comes Up
Most antidepressants never prompt anyone to ask whether they are controlled substances. SSRIs like sertraline or fluoxetine have essentially no recreational appeal. Bupropion is different because it works on dopamine and norepinephrine rather than serotonin. It blocks the reuptake of both of these neurotransmitters at their plasma membrane transporters, and its core chemical structure, an alpha-aminophenone, is shared with cathinone, which is a recognized drug of abuse.1PubMed Central. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release Cathinone is the active ingredient in khat and the parent compound of “bath salts” (synthetic cathinones), both of which are Schedule I controlled substances. So bupropion is, in a real chemical sense, a close relative of substances the government considers dangerous.
Despite that family resemblance, bupropion behaves differently in the brain when taken as prescribed. It inhibits dopamine and norepinephrine reuptake rather than flooding the synapse the way classic stimulants do. The distinction matters: preclinical evidence shows bupropion has some potential for misuse based on psychomotor stimulation and self-administration tests in animals, but that potential is less than what is seen with commonly misused stimulants. Studies in humans similarly indicate that bupropion shares some subjective effects with stimulants but lacks key reinforcing effects that drive compulsive use.2PubMed. Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential When taken orally at prescribed doses, the drug enters the brain gradually enough that it does not produce the rapid dopamine spike associated with addictive stimulants. An expert review of the naltrexone/bupropion combination for obesity flatly stated that unlike other centrally acting weight-loss drugs, the bupropion component has no abuse potential.3PubMed Central. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Where Misuse Actually Happens
If bupropion lacks the reinforcing punch of a true stimulant when swallowed, why does misuse happen at all? The answer almost always involves non-oral routes. A systematic review of clinical presentations found that bupropion misuse through snorting crushed tablets (insufflation) or dissolving and injecting them intravenously occurs almost exclusively in people with an existing substance use disorder, particularly those with a history of stimulant misuse or multiple substance use disorders. Many were also dual-diagnosis patients with ADHD and stimulant use disorder who had been prescribed bupropion therapeutically.4Journal of Clinical Psychopharmacology. Clinical Presentations of Bupropion Prescription Drug Misuse: A Systematic Review When snorted or injected, bupropion reaches the brain much faster than when absorbed through the gut, and users describe the result as a milder, briefer version of a cocaine high, with less intense withdrawal symptoms like anxiety and agitation.
The correctional system has drawn particular attention. Reports from U.S. prisons describe bupropion being diverted, traded, and misused, leading some facilities to restrict or discontinue prescribing it. One review concluded that in incarcerated populations, bupropion carries significant misuse and diversion potential.5PubMed. Bupropion diversion and misuse in the correctional facility The phenomenon has been widely discussed in corrections health literature, yet a systematic review looking for rigorous studies on the actual prevalence of bupropion abuse in U.S. prisons found no original research meeting its eligibility criteria, highlighting how poorly understood the scope of the problem remains.6PubMed Central. A Systematic Review of Abuse or Overprescription of Bupropion in American Prisons and a Synthesis of Case Reports on Bupropion Abuse in American Prison and Non-prison Systems In other words, the anecdotes are alarming, but we still do not have solid numbers on how widespread the problem is.
Medical Dangers of Non-Oral Use
When bupropion is misused through injection or insufflation, the risks go well beyond what you would see from taking an extra oral dose. The most common adverse effect at the time people seek emergency care is a rapid heart rate, followed by seizures.4Journal of Clinical Psychopharmacology. Clinical Presentations of Bupropion Prescription Drug Misuse: A Systematic Review Seizure risk is already one of the best-known side effects of bupropion even at therapeutic doses, and it rises sharply when more drug hits the brain at once.
Intravenous injection carries its own brutal set of complications. Case reports document tissue necrosis, cellulitis, and compartment syndrome at injection sites. Tablet binders and fillers that are harmless when swallowed wreak havoc on blood vessels and soft tissue when injected directly into a vein. At least two documented cases involved tissue necrosis and psychosis following IV bupropion use, with one patient developing compartment syndrome severe enough to require surgical intervention.7PubMed. Bupropion injection resulting in tissue necrosis and psychosis: previously undocumented complications of intravenous bupropion use disorder Digital ischemia, where blood flow to fingers is cut off, has also been reported.
What Happens in Overdose
Overdose risk from oral bupropion is a separate concern from misuse and is relevant to anyone taking the medication. After an overdose, the effects concentrate on the nervous system, the cardiovascular system, and the gut. Neurological effects can include tremor, confusion, agitation, hallucinations, coma, and seizures.8PubMed Central. Seizures after overdoses of bupropion intake Seizures are the most feared complication and can occur even in people with no history of epilepsy.
On the heart side, a study of 17 overdose patients found that roughly three-quarters developed tachycardia and nearly half had high blood pressure. The same study measured significantly prolonged QTc intervals compared to controls, meaning the heart’s electrical recovery was delayed.9PubMed. Bupropion overdose: QTc prolongation and its clinical significance Lab work has shown that bupropion blocks a specific potassium channel in the heart (responsible for what cardiologists call the IKr current), which explains the QT prolongation. It also disrupts gap junctions between heart cells, which accounts for QRS widening on an ECG, a separate type of conduction disturbance.10PubMed. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile
The reassuring part of the overdose picture is that these cardiac effects tend to resolve. A review covering 116 overdose patients across 13 published reports found that only 3 exhibited clear cardiotoxicity, and all 3 recovered within two to four days. None of the conduction delays progressed to a life-threatening rhythm.11PubMed. Cardiotoxicity following bupropion overdose That is a far better safety profile than tricyclic antidepressant overdoses, where fatal arrhythmias are a real and common danger.
False Positive Drug Tests
If you take bupropion and are subject to urine drug screening for work, probation, or medical treatment, there is a practical wrinkle worth knowing about. Bupropion and its metabolites can trigger a false positive result for amphetamines on certain immunoassay-based urine drug screens. One large study reviewed over 10,000 urine drug screens and found that 362 were positive for amphetamine. Of those, about a third failed to confirm on more precise gas chromatography testing. Among the unconfirmed positives, prescriptions for bupropion accounted for 41%, making it the most frequent single cause of false positive amphetamine screens in that population.12PubMed Central. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay
The problem is not universal across all test kits. Research into specific enzyme-linked immunosorbent assay kits found that at least two commonly used screening products will report a false positive for amphetamine when bupropion metabolites are present at concentrations above 500 ng/mL, which is achievable at normal therapeutic doses.13Therapeutic Drug Monitoring. Crossreactivity of Bupropion Metabolite With Enzyme-Linked Immunosorbent Assays Designed to Detect Amphetamine in Urine If this happens to you, a confirmatory test using mass spectrometry will clear things up, since the chemical signatures of bupropion metabolites and actual amphetamines are easy to distinguish once a lab looks more carefully. But knowing this possibility exists can save you a stressful conversation with an employer or parole officer. Carry documentation of your prescription if you are regularly screened.
Why Bupropion Remains Unscheduled
Given all of the above, you might wonder why regulators have not placed any restrictions on bupropion. The short answer is that the pattern of misuse does not look like what scheduling is designed to address. The oral form taken as prescribed does not produce a reinforcing high. Misuse overwhelmingly occurs through non-oral routes, in populations already dealing with substance use disorders, and often in institutional settings where access to preferred drugs is limited. Scheduling a medication adds friction to every legitimate prescription, and bupropion serves millions of people for depression, smoking cessation, and other uses. The regulatory calculation weighs the population-level cost of restricting access against the concentrated risk of misuse in a narrow group.
Some correctional facilities have addressed the issue on their own, restricting bupropion from their formularies or implementing directly observed therapy so that inmates cannot hoard or divert tablets. These facility-level decisions effectively treat bupropion as a controlled substance within that environment without requiring federal scheduling.
What Bupropion Is Actually Prescribed For
Bupropion has two FDA-approved indications: major depressive disorder and smoking cessation. As an antidepressant, reviews have found it is better than placebo and performs comparably to SSRIs like escitalopram.14PubMed Central. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation For quitting smoking, it is one of the few non-nicotine pharmacological tools available and shows added benefit when combined with nicotine replacement therapy. It is also used as part of a combination product with naltrexone for weight management.
Beyond its approved uses, bupropion has attracted research interest in addiction medicine. Its dopaminergic effects make it a natural candidate for helping people reduce their use of stimulant drugs, since it might partially substitute for the neurochemical effects they are seeking. A clinical trial in methamphetamine-dependent patients found that bupropion, combined with behavioral group therapy, significantly increased weeks of abstinence in male patients who had lower baseline methamphetamine use.15PubMed. Bupropion for the treatment of methamphetamine dependence A larger trial testing extended-release injectable naltrexone plus oral bupropion against placebo for methamphetamine use disorder found that the combination produced a response rate of about 14% compared with roughly 2.5% for placebo, a statistically significant difference, though the absolute numbers underscore how difficult methamphetamine addiction is to treat.16PubMed Central. Bupropion and Naltrexone in Methamphetamine Use Disorder Its clinical profile has also been studied in ADHD, although the evidence there remains mixed and limited by small trials.14PubMed Central. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation
How Bupropion Compares to Medications That Are Scheduled
The comparison people usually have in mind is with prescription stimulants like amphetamine (Adderall) and methylphenidate (Ritalin), both Schedule II controlled substances with strict prescribing rules. Those drugs produce rapid, powerful dopamine surges that the brain’s reward circuitry reads as strongly reinforcing. They carry real physical dependence risk even at therapeutic doses, and their street value makes diversion a constant concern. Bupropion’s effect on dopamine is gentler and slower when taken orally, which is why it does not produce the same subjective buzz and why regulators have not felt the need to schedule it.
Another useful comparison is with gabapentin. Like bupropion, gabapentin is not federally scheduled but has shown enough misuse potential that several U.S. states have classified it as a controlled substance at the state level. No state has done the same for bupropion as of this writing, but the gabapentin example shows that federal non-scheduling is not the final word. States can and do act independently when they see patterns of diversion in their populations.
The Structural Irony of Treating Addiction With a Misusable Drug
There is a genuine tension in bupropion’s clinical profile. The same dopaminergic properties that make it useful for treating depression without sexual side effects, for helping people quit smoking, and for potentially reducing stimulant cravings are exactly the properties that make it attractive to people looking for a stimulant substitute when preferred drugs are unavailable. This is not unique to bupropion; methadone, used to treat opioid addiction, is itself an opioid and a Schedule II controlled substance. Bupropion’s version of this tension is milder, but it is real, and it plays out most visibly in correctional settings and addiction treatment programs where patients have a history of stimulant use and are prescribed bupropion for depression or smoking cessation.
Clinicians in these settings face a judgment call. Withholding an effective antidepressant from someone with a substance use history carries its own risks, including untreated depression fueling relapse. Prescribing it introduces a diversion risk. The emerging consensus seems to lean toward prescribing with safeguards rather than blanket prohibition, but as the evidence gap around prison-based misuse shows, we are still making these decisions with incomplete data.6PubMed Central. A Systematic Review of Abuse or Overprescription of Bupropion in American Prisons and a Synthesis of Case Reports on Bupropion Abuse in American Prison and Non-prison Systems